6 min listen
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus Disease in High-Risk Kidney Transplant Recipients
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus Disease in High-Risk Kidney Transplant Recipients
ratings:
Length:
18 minutes
Released:
Jul 3, 2023
Format:
Podcast episode
Description
Valganciclovir is standard cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant recipients, but its use is limited by myelosuppression. JAMA Deputy Editor Preeti Malani, MD, MSJ, interviews Ajit Limaye, MD, from the University of Washington, about a multinational randomized trial of letermovir vs valganciclovir for CMV prevention in CMV-negative patients receiving a kidney from a CMV-positive donor. Related Content: Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients
Released:
Jul 3, 2023
Format:
Podcast episode
Titles in the series (100)
Substituted Interests and Best Judgments: An Integrated Model of Surrogate Decision Making: Interview with Daniel P. Sulmasy, MD, PhD, author of Substituted Interests and Best Judgments: An Integrated Model of Surrogate Decision Making by JAMA Author Interviews